Bhasin Arrti A, MacRae Jennifer M, Manns Braden, Leung Kelvin C W, Molnar Amber O, Busse Jason W, Collister David, Brimble K Scott, Rabbat Christian G, Tyrwhitt Jessica, Mazzetti Andrea, Walsh Michael
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Department of Medicine, University of Calgary, AB, Canada.
Can J Kidney Health Dis. 2024 Mar 25;11:20543581241237322. doi: 10.1177/20543581241237322. eCollection 2024.
Individuals receiving hemodialysis often experience concurrent symptoms during treatment and frequently report feeling unwell after dialysis. The degree to which intradialytic symptoms are related, and which specific symptoms may impair health-related quality of life (HRQoL) is uncertain.
To explore intradialytic symptoms clusters, and the relationship between intradialytic symptom clusters with dialysis treatment recovery time and HRQoL.
DESIGN/SETTING: We conducted a post hoc analysis of a prospective cohort study of 118 prevalent patients receiving hemodialysis in two centers in Calgary, Alberta and Hamilton, Ontario, Canada.
Adults receiving hemodialysis treatment for at least 3 months, not scheduled for a modality change within 6 weeks of study commencement, who could provide informed consent and were able to complete English questionnaires independently or with assistance.
Participants self-reported the presence (1 = to 5 = ) of 10 symptoms during each dialysis treatment, the time it took to recover from each treatment, and weekly Kidney Disease Quality of Life 36-Item-Short Form (KDQoL-36) assessments. Principal component analysis identified clusters of intradialytic symptoms. Mixed-effects, ordinal and linear regression examined the association between symptom clusters and recovery time (categorized as 0, >0 to 2, >2 to 6, or >6 hours), and the physical component and mental component scores (PCS and MCS) of the KDQoL-36.
One hundred sixteen participants completed 901 intradialytic symptom questionnaires. The most common symptom was lack of energy (56% of treatments). Two intradialytic symptom clusters explained 39% of the total variance of available symptom data. The first cluster included bone or joint pain, muscle cramps, muscle soreness, feeling nervous, and lack of energy. The second cluster included nausea/vomiting, diarrhea and chest pain, and headache. The first cluster (median score: -0.56, 25th to 75th percentile: -1.18 to 0.55) was independently associated with longer recovery time (odds ratio [OR] 1.62 per unit difference in score, 95% confidence interval [CI]: 1.23-2.12) and decreased PCS (-0.72 per unit difference in score, 95% CI: -1.29 to -0.15) and MCS scores (-0.82 per unit difference in score, 95% CI: -1.48 to -0.16), whereas the second cluster was not (OR 1.24, 95% CI: 0.97-1.58; PCS 0.19, 95% CI -0.46 to 0.83; MCS -0.72, 95% CI: -1.50 to 0.06).
This was an exploratory analysis of a small data set from 2 centers. Further work is needed to externally validate these findings to confirm intradialytic symptom clusters and the generalizability of our findings.
Intradialytic symptoms are correlated. The presence of select intradialytic symptoms may prolong the time it takes for a patient to recover from a dialysis treatment and impair HRQoL.
接受血液透析的患者在治疗期间常并发多种症状,且经常报告透析后感觉不适。透析期间症状之间的关联程度以及哪些特定症状可能损害健康相关生活质量(HRQoL)尚不确定。
探讨透析期间症状群,以及透析期间症状群与透析治疗恢复时间和HRQoL之间的关系。
设计/地点:我们对加拿大艾伯塔省卡尔加里市和安大略省汉密尔顿市两个中心的118名接受血液透析的现患患者进行了一项前瞻性队列研究的事后分析。
接受血液透析治疗至少3个月、在研究开始后6周内未计划改变透析方式、能够提供知情同意书且能够独立或在协助下完成英文问卷的成年人。
参与者在每次透析治疗期间自我报告10种症状的存在情况(1 = 有至5 = 无)、每次治疗后恢复所需的时间,以及每周进行的肾脏病生活质量36项简表(KDQoL-36)评估。主成分分析确定了透析期间症状群。混合效应、有序和线性回归分析了症状群与恢复时间(分为0、>0至2、>2至6或>6小时)以及KDQoL-36的身体成分和精神成分得分(PCS和MCS)之间的关联。
116名参与者完成了901份透析期间症状问卷。最常见的症状是精力不足(56%的治疗)。两个透析期间症状群解释了可用症状数据总方差的39%。第一个症状群包括骨或关节疼痛、肌肉痉挛、肌肉酸痛、感觉紧张和精力不足。第二个症状群包括恶心/呕吐、腹泻、胸痛和头痛。第一个症状群(中位数得分:-0.56,第25至75百分位数:-1.18至0.55)与更长的恢复时间(得分每单位差异的比值比[OR]为1.62,95%置信区间[CI]:1.23 - 2.12)以及PCS得分降低(得分每单位差异为-0.72,95% CI:-1.29至-0.15)和MCS得分降低(得分每单位差异为-0.82,95% CI:-1.48至-0.16)独立相关,而第二个症状群则不然(OR 1.24,95% CI:0.97 - 1.58;PCS 0.19,95% CI -0.46至0.83;MCS -0.72,95% CI:-1.50至0.06)。
这是对来自2个中心的小数据集的探索性分析。需要进一步开展工作以外部验证这些发现,从而确认透析期间症状群以及我们研究结果的普遍性。
透析期间症状相互关联。某些透析期间症状的出现可能会延长患者从透析治疗中恢复的时间,并损害HRQoL。